Liposcience Inc (LPDX) Financial Statements (2023 and earlier)

Company Profile

Business Address 2500 SUMNER BOULEVARD
RALEIGH, NC 27616
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2835 - In Vitro and In Vivo Diagnostic Substances (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

12/31/2013
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments
Cash and cash equivalents
Receivables
Inventory, net of allowances, customer advances and progress billings
Inventory
Other undisclosed current assets
Total current assets:
Noncurrent Assets
Property, plant and equipment
Intangible assets, net (including goodwill)
Intangible assets, net (excluding goodwill)
Restricted cash and investments
Deferred costs
Other noncurrent assets
Total noncurrent assets:
TOTAL ASSETS:
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities
Accounts payable
Other undisclosed current liabilities
Total current liabilities:
Noncurrent Liabilities
Liabilities, other than long-term debt
Other liabilities
Total noncurrent liabilities:
Total liabilities:
Equity
Equity, attributable to parent
Common stock
Additional paid in capital
Accumulated deficit
Total equity:
TOTAL LIABILITIES AND EQUITY:

Income Statement (P&L) ($ in thousands)

12/31/2013
Revenues
(Revenue, Net)
Cost of revenue
(Cost of Goods and Services Sold)
Other undisclosed gross profit
Gross profit:
Operating expenses
Operating loss:
Nonoperating income
Investment income, nonoperating
Interest and debt expense
Loss from continuing operations:
Loss before gain (loss) on sale of properties:
Net loss available to common stockholders, diluted:

Comprehensive Income ($ in thousands)

12/31/2013
Net loss:
Comprehensive loss, net of tax, attributable to parent:

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: